Clasificación en acciones
#4588
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Capitalización bursátil
$3.51B
Comercio UniQure N.V. (QURE)
Precio QURE con Capital del mercado a B
Capitalización de mercado de UniQure N.V.(QURE)
Capitalización bursátil: $3.51B
A fecha de August 2026, UniQure N.V. tiene una capitalización de mercado de $3.51B. Esto convierte a UniQure N.V. en la 4588th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de UniQure N.V. desde 2014 hasta 2026
QURE en comparación con los más populares 5 títulos stocks
| Precio por QURE |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.088T
|
+144,669.88%
|
|
|
|
|
$4.629T
|
+131,615.89%
|
|
|
|
|
$4.118T
|
+117,061.78%
|
|
|
|
|
$3.687T
|
+104,801.56%
|
|
|
|
|
$2.800T
|
+79,560.94%
|
